-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photos
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Leisure
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In-Depth
-
Weekend
-
Lifestyle
-
Diversions
-
Movies
-
Hotels and Food
-
Special Report
-
Yes Teens!
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Futian Today
-
Advertorial
-
CHTF Special
-
Focus
-
Guide
-
Nanshan
-
Hit Bravo
-
People
-
Person of the week
-
Majors Forum
-
Shopping
-
Investment
-
Tech and Vogue
-
Junior Journalist Program
-
Currency Focus
-
Food and Drink
-
Restaurants
-
Yearend Review
-
QINGDAO TODAY
在线翻译:
szdaily -> Special Report -> 
Pfizer, BioNTech begin COVID-19 vaccine human trial
    2020-05-07  08:53    Shenzhen Daily

PFIZER Inc. and BioNTech have started the human trial of a coronavirus vaccine, the companies announced Tuesday.

The first dosing of the BNT162 vaccine program began in Germany last week, according to a company statement. The trial phase aims to enroll up to 360 patients, aged 18 to 55. Once the younger group produces sound evidence of safety and immunogenicity, testing in older adults, or those between the ages of 65 and 85, will begin.

“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” said Albert Bourla, Pfizer CEO and chairman, in the statement.

U.S. sites dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will start “enrollment shortly,” according to the company statement.

The development program includes four vaccine candidates, each of which is a different combination of a messenger RNA (mRNA) format, important in protein synthesis, and target antigen.

The trial will evaluate the varying vaccine candidates to determine which results in the safest, most effective vaccine.

With the anticipation of success, Pfizer and BioNTech are scaling up production for global supply. The program will allow for the production of millions of vaccine doses in 2020, with hundreds of millions in production the following year.

There are 102 potential COVID-19 vaccines in development as of April 30, according to the World Health Organization. Eight have been approved for clinical trials.(SD-Agencies)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@szszd.com.cn